Extended Data Fig. 9: Neuronal clusters in the Vagal ganglia.
From: A body–brain circuit that regulates body inflammatory responses
a, Strategy for chemogenetic activation of vagal neuronal populations. An excitatory DREADD receptor (via AAV-DIO-hM3Dq) was targeted bilaterally to the nodose ganglia of Vip-cre, Gpr65-cre, Piezo2-cre and Oxtr-cre mice. The mice were then examined for changes in circulating cytokine levels in response to LPS in the presence of the DREADD receptor agonist CNO. Schematics in panel a were created using BioRender (https://biorender.com). b-e, The bar graphs show cytokine levels of IL-6, IL-1β and IL-10 in the peripheral blood of mice expressing either excitatory DREADD (hM3Dq) or control mCherry in VIP, GPR65, PIEZO2, OXTR vagal neurons, 2 h after LPS stimulation. All mice were injected with CNO 1 h prior to LPS. b, Vip: n = 4 each group; Mann–Whitney U-tests, p (IL-6) = 0.88, p (IL-1β) = 0.88, p (IL-10) = 0.2. c, Gpr65: n = 5 (control) and 4 (hM3Dq); Mann–Whitney U-tests, p (IL-6) = 0.03, p (IL-1β) = 0.06, p (IL-10) = 0.55. d, Piezo2: n = 5 each group; Mann–Whitney U-tests, p (IL-6) = 0.54, p (IL-1β) = 0.42, p (IL-10) = 0.42. e, Oxtr: n = 5 each group; Mann–Whitney U-tests, p (IL-6) = 0.84, p (IL-1β) = 0.65, p (IL-10) = 0.84. Values are means ± SEM; Activation of any of these vagal populations has no appreciable effect on LPS-induced cytokine responses.
